Abstract
Protein-protein interactions (PPI) play an important role in cellular signalling, the most common of which is the PDZ domain. This 90-residue domain occurs 257 times in 142 human proteins. Although these domains have well-defined binding sites which recognises short C-terminal peptide ligands (PLs), the high specificity of PDZ binding makes them an intriguing system to study. Abnormal PPI are of particular importance as they often contribute to the development of diseases. PDZ domains have been reported to be implicated in diseases such as cancer, cystic fibrosis, schizophrenia, Alzheimers, Parkinson, avian influenza, pain, and stroke. In this review, we present the structure of PDZ domains, highlighting the high specificity of their binding to endogenous PLs, leading to their classification. We also consider their involvement in disease pathways and expand on current efforts to modulate their interaction using modified peptides and small molecules as selective PDZ inhibitors.
Keywords: PDZ domain, protein-protein interaction (PPI), PDZ inhibitor
Current Chemical Biology
Title: Protein-Protein Interactions: Recent Progress in the Development of Selective PDZ Inhibitors
Volume: 3 Issue: 2
Author(s): Sylvie Ducki and Elizabeth Bennett
Affiliation:
Keywords: PDZ domain, protein-protein interaction (PPI), PDZ inhibitor
Abstract: Protein-protein interactions (PPI) play an important role in cellular signalling, the most common of which is the PDZ domain. This 90-residue domain occurs 257 times in 142 human proteins. Although these domains have well-defined binding sites which recognises short C-terminal peptide ligands (PLs), the high specificity of PDZ binding makes them an intriguing system to study. Abnormal PPI are of particular importance as they often contribute to the development of diseases. PDZ domains have been reported to be implicated in diseases such as cancer, cystic fibrosis, schizophrenia, Alzheimers, Parkinson, avian influenza, pain, and stroke. In this review, we present the structure of PDZ domains, highlighting the high specificity of their binding to endogenous PLs, leading to their classification. We also consider their involvement in disease pathways and expand on current efforts to modulate their interaction using modified peptides and small molecules as selective PDZ inhibitors.
Export Options
About this article
Cite this article as:
Ducki Sylvie and Bennett Elizabeth, Protein-Protein Interactions: Recent Progress in the Development of Selective PDZ Inhibitors, Current Chemical Biology 2009; 3 (2) . https://dx.doi.org/10.2174/2212796810903020146
DOI https://dx.doi.org/10.2174/2212796810903020146 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Human Papillomavirus Induced Cervical and Oropharyngeal Cancers: From Mechanisms to Potential Immuno-therapeutic Strategies
Current Drug Metabolism HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design Exploiting Cyclooxygenase-(in)Dependent Properties of COX-2 Inhibitors for Malignant Glioma Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting Cancer Cells with Photoactive Silica Nanoparticles
Current Pharmaceutical Design Curcumin: A Natural Pan-HDAC Inhibitor in Cancer
Current Pharmaceutical Design Antiangiogenic Therapy
Current Pharmaceutical Design Synthesis, Characterization, Antimicrobial and Antitumor Activities of Sucrose Octa(N-ethyl)carbamate
Medicinal Chemistry Anticarcinogenic Effects of Capsaicin-Loaded Nanoparticles on In vitro Hepatocellular Carcinoma
Current Chemical Biology Dynamic Contrast-Enhanced MRI in Oncology Drug Development
Current Clinical Pharmacology It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Current Medicinal Chemistry β-Carboline Alkaloids: Biochemical and Pharmacological Functions
Current Medicinal Chemistry Management of Locally Advanced Cancer Cervix an Indian Perspective
Reviews on Recent Clinical Trials Detection of Early Cancer: Genetics or Immunology? Serum Autoantibody Profiles as Markers of Malignancy
Anti-Cancer Agents in Medicinal Chemistry Drosophila Neoplasias: Clues Towards the Understanding of Human Cancers
Current Genomics Phytochemical Content and Potential Health Applications of Pecan [<i>Carya illinoinensis</i> (Wangenh) K. Koch] Nutshell
Current Topics in Medicinal Chemistry An Update on Developments in Female Hormonal Contraception
Current Women`s Health Reviews Rational Design of 5-Aminolevulinic Acid Derivatives Aimed at Improving Photodynamic Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Counselling and Cognitive Behaviour Interventions Delivered to Reduce Psychological Morbidity and Improve Quality of Life in Gynaecological Cancer Patients: Recent Achievements
Current Women`s Health Reviews Immunotherapy of Human Cancers Using Gene Modified T Lymphocytes
Current Gene Therapy Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors
Current Topics in Medicinal Chemistry